Visceral leishmaniasis (VL) is a serious parasitic disease causing considerable mortality
and major disability in the Indian subcontinent. It is most neglected tropical disease …

The state of Bihar in India carries the largest share of the world's burden of antimony-
resistant visceral leishmaniasis. We analysed clinical studies done in Bihar with different …

Liposomal amphotericin B has been used with increasing frequency to treat visceral
leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the …

Visceral leishmaniasis (VL) is a severe disease associated with considerable morbidity,
characterized by fever, hepatosplenomegaly, pancytopenia, and hypergammaglobulinemia …

Visceral leishmaniasis (VL) or kala-azar is known to be associated with a mixed Th1-Th2
response, and effective host defense requires the induction of IFN-γ and IL-12. We address …

Background Leishmaniasis is increasingly reported among travellers. Leishmania species
vary in sensitivity to available therapies. Fast and reliable molecular techniques have made …

Background: The treatment options for leishmaniasis are limited. Most of the drugs available
need parenteral administration, are toxic, require monitoring and have a prolonged …

Widespread antimony resistance renders conventional amphotericin B the only option for
the treatment of visceral leishmaniasis (VL) in North Bihar, India. Because of its excellent …

We compared the efficacy of amphotericin B and pentamidine isethionate in a prospective
randomised trial in 120 uncomplicated and parasitologically confirmed cases of antimony …

Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection
caused principally by Leishmania donovani and Leishmania infantum (known as …